Data reflect disparities in use of next-generation sequencing for lung cancer,

Patients appeared twice as likely to participate in clinical trials if they received biomarker testing before the start of first-line therapy (OR = 2.29; 95% CI, …, Patients appeared twice as likely to participate in clinical trials if they received biomarker testing before the start of first-line therapy (OR = 2.29; 95% CI, …, Read More

Scroll to Top